Cardiovascular

Stable angina: antianginal pharmacotherapy and lifestyle optimization

Clinical Overview and When to Suspect Stable Angina

— Symptoms are predictable: provoked by exertion or emotion, relieved within 5 minutes by rest or sublingual nitroglycerin.

— Unchanged in frequency, duration, or threshold for ≥2 months distinguishes it from unstable angina.

— Middle-aged or older adult with ≥1 ASCVD risk factor (HTN, DM, dyslipidemia, smoking, family history, CKD) presenting with exertional substernal pressure.

— Atypical presentations in women, diabetics, elderly, and post-transplant patients: dyspnea-equivalent, fatigue, epigastric discomfort, or jaw/arm pain only.

— Microvascular angina in women with normal coronaries but classic exertional pattern.

— Use age, sex, and symptom typicality (3 features: substernal, exertional, relieved by rest/NTG) to stratify low (<5%), intermediate (5–15%), or high (>15%) pretest probability.

— Avoid stress testing in very low-risk patients — high false-positive rate.

— Demand ischemia: HR × SBP (rate–pressure product) drives O₂ demand; antianginals target this.

— Supply limitation: fixed stenosis prevents coronary vasodilation reserve during exertion.

Definition: Stable angina is a reproducible pattern of chest discomfort caused by myocardial oxygen supply–demand mismatch, typically from a fixed atherosclerotic coronary stenosis ≥70% (or ≥50% left main).

When to suspect (Step 3 outpatient framing):

Pretest probability framework (CAD Consortium / 2021 AHA/ACC chest pain guideline):

Pathophysiology pearls:

Step 3 management: In a stable outpatient with new exertional chest pain and intermediate pretest probability, the first move is risk-factor optimization + stress testing, not immediate catheterization. Reserve cath for high-risk stress findings, refractory symptoms on optimal medical therapy (OMT), or LV dysfunction with angina.

Board pearl: ISCHEMIA trial (2020) showed no mortality benefit of routine early invasive strategy over OMT in stable CAD with moderate–severe ischemia — reinforces OMT-first paradigm on Step 3.

Presentation Patterns and Key History

— Substernal chest discomfort with characteristic quality (pressure, squeezing, heaviness, tightness) and duration (2–10 minutes).

— Provoked by exertion or emotional stress.

— Relieved by rest or sublingual nitroglycerin within ~5 minutes.

— Exertional dyspnea (diabetics, elderly, women).

— Epigastric burning mistaken for GERD.

— Jaw, neck, shoulder, or left arm discomfort without chest pain.

— Unexplained fatigue or near-syncope on exertion.

— I: Angina only with strenuous/prolonged exertion.

— II: Slight limitation; angina walking >2 blocks or >1 flight at normal pace.

— III: Marked limitation; angina at <2 blocks or 1 flight.

— IV: Angina at rest or with any activity.

— Crescendo pattern, rest pain, or new-onset within 2 months → unstable angina, not stable — admit, treat as ACS.

— Nocturnal chest pain relieved by sitting up → suspect heart failure or Prinzmetal variant.

— Pain reproduced by palpation, breathing, or position → favors musculoskeletal/pleuritic etiology.

— Postprandial worsening → consider mesenteric ischemia or esophageal spasm mimics.

— Smoking status and pack-years, BP control, LDL, A1c, BMI, family history of premature CAD (<55 M / <65 F first-degree relative), CKD, inflammatory disease (RA, SLE, HIV), prior chest radiation, cocaine/stimulant use.

Classic (typical) angina — all 3 features:

Atypical angina: 2 of 3 features. Noncardiac chest pain: ≤1 feature.

Anginal equivalents — high yield in special populations:

Canadian Cardiovascular Society (CCS) functional class — must know:

History elements that change management:

Risk factor inventory (every visit):

Key distinction: Stable angina = unchanged threshold for ≥2 months; unstable angina = new-onset, rest pain, or accelerating frequency/severity. The history alone — not troponin — drives this triage decision at the initial encounter.

Board pearl: Sexual activity, cold exposure, and heavy meals all raise rate–pressure product and can provoke angina; counsel patients to take prophylactic SL nitroglycerin 5 minutes before predictable triggers.

Physical Exam Findings (and Hemodynamic Assessment)

— Elevated BP and HR from sympathetic surge (or hypotension if extensive ischemia).

— S4 gallop: stiff, ischemic LV with atrial kick into noncompliant ventricle — classic transient sign.

— S3 gallop: suggests ischemic LV dysfunction — higher-risk finding.

— Transient mitral regurgitation murmur from papillary muscle ischemia — apical holosystolic, radiates to axilla.

— Paradoxical splitting of S2 from delayed LV ejection.

— Bibasilar crackles if ischemia precipitates pulmonary edema.

— Carotid, abdominal, femoral bruits → polyvascular disease.

— Diminished pedal pulses, hair loss on shins, ABI <0.9 → PAD coexistence.

— Xanthelasma, corneal arcus in younger patients → familial hyperlipidemia.

— Retinal AV nicking, copper wiring → chronic HTN.

— Reproducible chest wall tenderness → costochondritis (but does not exclude CAD).

— Pericardial friction rub → pericarditis.

— Asymmetric BP/pulses, early diastolic murmur → aortic dissection.

— Pleural rub, unilateral leg swelling → PE.

— Aortic stenosis murmur (late-peaking SEM, soft S2) → can cause exertional angina without obstructive CAD.

— Resting HR (target ~55–60 bpm on β-blocker if symptomatic).

— BP (goal <130/80 in CAD per ACC/AHA 2017).

— BMI, waist circumference.

Between episodes: Exam is often completely normal — a normal exam never rules out CAD.

During an anginal episode — transient findings:

Signs of underlying atherosclerosis (always look):

Signs that change the differential:

Hemodynamic vitals to chart at every visit:

CCS pearl: When simulating an outpatient stable angina visit, order vitals, full cardiovascular exam, peripheral pulses, and 12-lead ECG at the initial encounter even if asymptomatic — establishes baseline for comparison.

Board pearl: A new exertional murmur of MR in a patient with chest pain is transient papillary muscle ischemia until proven otherwise — pursue stress imaging or cath, not just echo at rest.

Diagnostic Workup — Initial Labs, ECG, and Imaging

— Normal in ~50% of stable angina — does not exclude CAD.

— Look for: pathologic Q waves (prior MI), LVH with strain, LBBB, nonspecific ST-T changes, arrhythmia.

— LBBB or paced rhythm → exercise ECG uninterpretable; choose imaging-based stress.

— Lipid panel (fasting or non-fasting acceptable per 2018 AHA/ACC).

— Fasting glucose and/or HbA1c — screen for diabetes/prediabetes.

— CBC (anemia worsens angina by reducing O₂ delivery).

— TSH (hyper/hypothyroidism alters demand and lipid profile).

— Basic metabolic panel including creatinine/eGFR (drug dosing, contrast risk).

— LFTs before statin initiation (baseline only; not routine monitoring).

— hs-troponin only if ACS suspected; not routine in chronic stable angina.

— Not routine. Order if HF, valvular disease, or alternative diagnosis (aortic dissection, pneumothorax) suspected.

— Look for cardiomegaly, pulmonary congestion, calcified aorta.

— Indicated if suspected HF, prior MI, murmur, abnormal ECG, or ventricular arrhythmia.

— Assesses LVEF (drives β-blocker, ACEi, ICD decisions), regional wall motion (prior infarct), valvular disease, diastolic function.

— Useful in low–intermediate pretest probability or asymptomatic risk stratification (borderline ASCVD 5–20%).

— CAC = 0 has high negative predictive value; CAC >100 supports statin and possibly further testing.

Resting 12-lead ECG (all patients):

Initial laboratory panel:

Chest X-ray:

Resting transthoracic echocardiogram:

Coronary artery calcium (CAC) score:

Step 3 management: For a stable outpatient with new exertional chest pain: order ECG, lipid panel, A1c, CBC, BMP, TSH, and resting echo if indicated, then proceed to stress testing — do not order troponin unless presentation is acute.

Key distinction: Troponin elevation in chronic stable angina warrants reclassification toward NSTE-ACS or myocardial injury — escalate, do not continue outpatient workup.

Diagnostic Workup — Stress Testing and Advanced Imaging

— Coronary CT angiography (CCTA) preferred — excellent NPV, rules out obstructive CAD.

— Best in younger patients, women, those with atypical symptoms.

— Stress testing with imaging preferred over plain exercise ECG when available.

— Use only if patient can exercise AND baseline ECG is interpretable (no LBBB, paced rhythm, LVH with strain, digoxin, WPW, resting ST depression >1 mm).

— Positive: ≥1 mm horizontal/downsloping ST depression.

— High-risk findings (Duke treadmill score ≤ −11, ST depression at low workload, hypotensive response, ST elevation, sustained VT) → proceed to coronary angiography.

— Stress echo (exercise or dobutamine): wall motion abnormalities; no radiation.

— Nuclear MPI (SPECT/PET): reversible perfusion defects; preferred if obese, LBBB (use vasodilator, not exercise).

— Stress cardiac MRI: highest spatial resolution; useful when echo windows poor.

— Vasodilators (regadenoson, adenosine, dipyridamole): contraindicated in severe reactive airway disease, high-grade AV block, recent caffeine.

— Dobutamine: avoid in severe HTN, arrhythmias, aortic dissection.

— High-risk noninvasive findings.

— Refractory angina despite OMT.

— LVEF <50% with angina.

— Survivors of sudden cardiac death or sustained VT.

— Occupational requirement (pilots) or diagnostic uncertainty.

2021 AHA/ACC chest pain guideline framework — choose modality by pretest probability and patient factors:

Low pretest probability (<5–15%):

Intermediate–high pretest probability (>15%):

Exercise ECG (treadmill):

Stress imaging modalities:

Pharmacologic stress agents:

Invasive coronary angiography — indications:

FFR/iFR: Functional assessment of intermediate (40–70%) lesions; FFR ≤0.80 → hemodynamically significant.

Board pearl: LBBB + need for stress test = pharmacologic vasodilator MPI or PET, never exercise (false-positive septal defects from delayed activation).

CCS pearl: Order CCTA in a 45-year-old woman with atypical chest pain and low–intermediate probability — high NPV avoids unnecessary catheterization.

Risk Stratification and First-Line Management Logic

— 1. Reduce mortality and MI: aspirin, statin, ACEi/ARB (if indicated), risk factor control.

— 2. Improve symptoms and quality of life: β-blockers, CCBs, nitrates, ranolazine.

— High-risk markers (any one triggers angiography consideration):

— LVEF <35% at rest or <45% post-stress.

— Large reversible perfusion defect (>10% myocardium).

— Multiple moderate defects or anterior defect.

— Stress-induced LV dilation or transient ischemic dilation.

— Duke treadmill score ≤ −11.

— Exercise-induced hypotension, ST elevation, or sustained VT.

— Low-risk markers: small/absent defects, Duke score ≥+5, normal LVEF.

— In stable CAD with moderate–severe ischemia, invasive strategy did not reduce death or MI vs. OMT over 3.2 years.

— Invasive strategy did improve angina-related QOL, especially in those with frequent angina.

— Excluded: LM disease, LVEF <35%, ACS, NYHA III–IV HF.

— Step 1: Lifestyle + aspirin + high-intensity statin + ACEi (if HTN, DM, HF, CKD).

— Step 2: Add β-blocker as first-line antianginal (especially post-MI, LV dysfunction).

— Step 3: Add or substitute CCB (non-DHP if no β-blocker; DHP if on β-blocker).

— Step 4: Add long-acting nitrate; ensure nitrate-free interval (10–12 h).

— Step 5: Add ranolazine for refractory symptoms.

— Step 6: Refractory despite OMT → coronary angiography for revascularization.

Goals of stable angina therapy — memorize these two pillars:

Risk stratification informs invasive vs. medical strategy:

ISCHEMIA trial implications (2020):

Practical algorithm (Step 3 framing):

Step 3 management: Always document a 3-month OMT trial before referring stable angina patients for catheterization unless high-risk features are present.

Board pearl: The two interventions with proven mortality benefit in stable CAD are smoking cessation and statin therapy — exceed even revascularization in long-term mortality reduction.

Pharmacotherapy — First-Line Antianginal Drug Regimen

— Mechanism: ↓HR, ↓contractility, ↓BP → ↓myocardial O₂ demand; prolongs diastole → ↑coronary perfusion.

— Preferred agents: metoprolol succinate, bisoprolol, carvedilol, atenolol.

— Target resting HR 55–60 bpm; exercise HR <75% of ischemic threshold.

— Mandatory post-MI and in LVEF <40%.

— Contraindications: severe bradycardia, high-grade AV block (without pacer), decompensated HF, severe reactive airway disease (relative — cardioselective often tolerated).

— Watch for: fatigue, depression, erectile dysfunction, masking hypoglycemia in DM.

— Non-dihydropyridines (verapamil, diltiazem): ↓HR and contractility — useful if β-blocker contraindicated. Do NOT combine with β-blocker (risk of bradycardia, AV block, HF).

— Dihydropyridines (amlodipine, felodipine): peripheral vasodilation, ↓afterload. Safe to combine with β-blocker. Avoid short-acting nifedipine (reflex tachycardia, ↑mortality).

— Verapamil/diltiazem contraindicated in LVEF <40%.

— Sublingual nitroglycerin (0.3–0.4 mg): acute angina relief and pre-exertional prophylaxis. Take, repeat q5 min × 3; if persistent → call 911.

— Long-acting nitrates (isosorbide mononitrate 30–120 mg daily; isosorbide dinitrate): require 10–12 hour nitrate-free interval to prevent tachyphylaxis.

— Contraindicated with PDE5 inhibitors (sildenafil within 24 h, tadalafil within 48 h) — fatal hypotension. Also avoid in HCM and severe AS.

— Late sodium current inhibitor; does not affect HR or BP — ideal when bradycardia/hypotension limit other agents.

— Prolongs QT (avoid with other QT-prolongers); metabolized by CYP3A4 (avoid diltiazem, verapamil, macrolides).

β-Blockers — first-line antianginal:

Calcium channel blockers — first-line alternative or add-on:

Nitrates:

Ranolazine:

Board pearl: Combining verapamil + β-blocker is a classic Step 3 wrong-answer trap — risks symptomatic bradycardia and heart block. Use amlodipine instead.

Step 3 management: Start β-blocker first; titrate to HR 55–60. If symptoms persist, add amlodipine or long-acting nitrate next.

Mortality-Reducing Therapy and Refractory Angina Management

— Aspirin 75–100 mg daily indefinitely — reduces MI and CV death.

— Clopidogrel 75 mg if aspirin-intolerant.

— Post-PCI DAPT: aspirin + P2Y12 inhibitor (clopidogrel typically) for 6 months after DES in stable CAD; can shorten to 1–3 months if high bleeding risk.

— Atorvastatin 40–80 mg or rosuvastatin 20–40 mg.

— Goal: ≥50% LDL reduction; LDL <70 mg/dL (consider <55 in very high-risk per 2022 ACC).

— If LDL still ≥70 on max statin + lifestyle: add ezetimibe, then PCSK9 inhibitor (alirocumab/evolocumab) or inclisiran, or bempedoic acid if statin-intolerant.

— Check lipid panel 4–12 weeks after initiation/change, then annually.

— Mandatory if HTN, DM, CKD, LVEF <40%, or prior MI.

— Reasonable in all stable CAD (HOPE, EUROPA trials).

— PCI: symptom relief in single/multi-vessel disease; no mortality benefit over OMT in stable CAD (COURAGE, ISCHEMIA).

— CABG preferred over PCI:

— Left main disease (especially complex).

— 3-vessel CAD, particularly with diabetes (FREEDOM trial) or LVEF <35%.

— High SYNTAX score (>33).

— Add ranolazine; consider enhanced external counterpulsation (EECP), spinal cord stimulation, or cardiac rehab intensification.

Antiplatelet therapy:

High-intensity statin (all stable CAD patients regardless of LDL):

ACEi/ARB:

SGLT2 inhibitors / GLP-1 RAs: In diabetic CAD patients, prefer empagliflozin, dapagliflozin, or semaglutide/liraglutide for cardiovascular risk reduction independent of glycemic control.

Influenza and COVID-19 vaccination annually — reduces cardiac events.

Revascularization — when OMT fails or high-risk anatomy:

Refractory angina (despite max OMT, not revascularizable):

CCS pearl: In a diabetic with 3-vessel CAD and LVEF 30%, refer to cardiothoracic surgery for CABG — not PCI. This is a recurring Step 3 stem.

Board pearl: Stable CAD discharge "ABCDE": Aspirin/ACEi, Beta-blocker/BP, Cholesterol/Cigarettes, Diet/Diabetes, Exercise/Education.

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher prevalence of atypical presentations (dyspnea, confusion, fatigue).

— Increased risk of polypharmacy, orthostasis, falls, and bleeding.

— Start low, go slow with β-blockers, nitrates, ACEi — orthostatic hypotension is common.

— Verapamil/diltiazem: risk of bradycardia, constipation, worsening HF.

— Statins remain beneficial; very-high-intensity dosing may be moderated in frail >80 — shared decision-making.

— Aspirin for secondary prevention is still indicated; primary prevention generally avoided in ≥70 (2019 ACC/AHA) due to bleeding risk.

— Bleeding risk on antiplatelets ↑ with PPI co-prescription consideration if history of GI bleed.

— Stage 3–5 CKD is a CAD risk equivalent. Aggressive lipid and BP control essential.

— Atorvastatin and fluvastatin do not require renal dose adjustment; rosuvastatin: cap at 10 mg if eGFR <30.

— ACEi/ARB: tolerate creatinine rise up to 30% and K up to 5.5; hold if greater.

— Atenolol, sotalol, nadolol are renally cleared — prefer metoprolol or carvedilol.

— Avoid nephrotoxins around contrast studies; hydrate before CCTA/angiography.

— Ranolazine: avoid if eGFR <30 (limited data, QT risk).

— Statins: caution in active liver disease; NASH and compensated cirrhosis are NOT contraindications to statins. Discontinue only for ALT >3× ULN persistently.

— Verapamil, diltiazem, metoprolol, propranolol all undergo extensive hepatic metabolism — reduce dose.

— Ranolazine contraindicated in moderate–severe hepatic impairment (Child-Pugh B/C).

— Assess functional status, fall risk, cognition before intensifying regimen.

— Deprescribe nitrates if causing syncope; consider ranolazine (no BP/HR effect).

Elderly (≥75 years):

CKD (eGFR <60):

Hepatic impairment:

Frailty considerations:

Step 3 management: In an 82-year-old with stable angina, recurrent falls, and BP 110/65, reduce or stop long-acting nitrate, continue β-blocker at low dose, prioritize statin and aspirin — quality of life over aggressive HR targets.

Board pearl: Avoid atenolol in CKD — accumulates and causes profound bradycardia.

Special Populations — Women, Pregnancy, and Younger Patients

— More likely to present with atypical symptoms, microvascular angina (INOCA), or vasospastic angina.

— Lower diagnostic yield from exercise ECG — favor stress imaging or CCTA.

— Coronary microvascular dysfunction: classic exertional angina with normal coronaries → manage with β-blocker, ACEi, statin, and consider ranolazine.

— SCAD (spontaneous coronary artery dissection): peripartum or young women with chest pain — typically managed conservatively (not stented) unless ongoing ischemia.

— CAD in pregnancy is rare but rising with delayed childbearing, obesity, DM.

— Safe antianginals: metoprolol, labetalol (β-blockers — monitor for fetal growth restriction, neonatal bradycardia, hypoglycemia); nitrates (acute use).

— Avoid: ACEi/ARB (teratogenic, oligohydramnios — category D), statins (category X historically; recent FDA update relaxed restriction, but generally hold during pregnancy unless homozygous FH).

— Aspirin low-dose (81 mg) is safe and indicated for preeclampsia prevention in high-risk women.

— Avoid amiodarone, warfarin (1st trimester teratogen).

— Metoprolol, propranolol, captopril, enalapril, and warfarin compatible.

— Atenolol concentrates in breast milk — avoid.

— Statins not recommended during lactation.

— Familial hypercholesterolemia (LDL >190, tendon xanthomas, family history).

— Cocaine/methamphetamine-induced ischemia.

— Coronary anomalies, myocardial bridging.

— Vasculitis (Kawasaki sequelae, Takayasu).

— Antiphospholipid syndrome, HIV-related accelerated atherosclerosis.

— Premature MI in first-degree relative <55 (M) or <65 (F).

Women with stable angina:

Pregnancy:

Lactation:

Young patients (<45 years) with angina — search for unusual causes:

Key distinction: Microvascular angina (women, normal coronaries, abnormal coronary flow reserve) vs. vasospastic/Prinzmetal angina (rest pain, often nocturnal, transient ST elevation, treated with CCBs — avoid β-blockers, which can worsen spasm).

Board pearl: Hold ACEi/ARB and statins in pregnant women with stable CAD; continue β-blocker (labetalol/metoprolol) and low-dose aspirin.

Complications and Adverse Outcomes

— Acute coronary syndrome: plaque rupture → UA, NSTEMI, STEMI. Risk persists despite stable symptoms — any change in pattern warrants re-evaluation.

— Ischemic cardiomyopathy: repeated demand ischemia or silent infarcts → LVEF decline, HF.

— Ventricular arrhythmias and sudden cardiac death: higher risk with LVEF <35%.

— Stroke: shared atherosclerotic substrate; ~2× risk vs. general population.

— β-blockers: bradycardia, AV block, fatigue, depression, erectile dysfunction, bronchospasm, masked hypoglycemia.

— Non-DHP CCBs: bradycardia, AV block, constipation, worsening systolic HF, gingival hyperplasia.

— DHP CCBs: pedal edema (not from HF — from precapillary dilation; treat by adding ACEi/ARB, not diuretic), flushing, headache, reflex tachycardia (short-acting only).

— Nitrates: headache (tachyphylactic), orthostatic hypotension, syncope, tolerance, methemoglobinemia (rare, high dose).

— Statins: myalgias (5–10%), rhabdomyolysis (rare), transaminitis, new-onset DM (small absolute increase), drug interactions via CYP3A4 (simvastatin/lovastatin most).

— Aspirin: GI bleed, hemorrhagic stroke.

— Ranolazine: QT prolongation, constipation, dizziness, nausea.

— PCSK9 inhibitors: injection-site reactions, flu-like symptoms.

— PCI: stent thrombosis (acute/subacute), restenosis, contrast nephropathy, access-site hematoma, retroperitoneal bleed.

— CABG: perioperative MI, AF (~30%), stroke, sternal wound infection, mediastinitis, graft failure.

Disease progression complications:

Medication-related adverse effects (test favorites):

Procedure-related complications (if revascularized):

Step 3 management: Pedal edema on amlodipine — do not add a diuretic; either reduce dose, switch to a different DHP, or add ACEi/ARB which counteracts precapillary dilation.

Board pearl: New muscle aches on a statin + dark urine + CK >10× ULN = rhabdomyolysis — stop statin immediately, hydrate, monitor renal function. Re-challenge with low-dose alternative statin (e.g., pravastatin) after recovery.

When to Escalate Care — Triage from Outpatient to Inpatient

— Chest pain at rest lasting >20 minutes.

— New-onset angina within 2 months (CCS III–IV severity).

— Crescendo pattern: increasing frequency, severity, or duration.

— Angina with syncope, hypotension, pulmonary edema, or new murmur.

— Anginal equivalent with diaphoresis, vomiting, or marked dyspnea.

— ECG changes: new ST depression ≥0.5 mm, T-wave inversion, ST elevation.

— Stable angina refractory to optimal medical therapy (≥2 antianginals).

— CCS class III symptoms limiting normal activities.

— Stress test with high-risk features (large reversible defect, low workload ischemia, post-exercise hypotension).

— LVEF <50% with anginal symptoms.

— Recurrent angina post-PCI within 12 months → consider in-stent restenosis or stent thrombosis.

— Diagnostic uncertainty.

— Pre-operative risk assessment in active angina before non-cardiac surgery.

— Complex polypharmacy or drug intolerance.

— Defer elective non-cardiac surgery for ≥30 days post-PCI with BMS or balloon, ≥6 months post DES (ideally 12 months) before stopping DAPT for surgery.

— Continue aspirin perioperatively for most cardiac patients undergoing non-cardiac surgery; hold P2Y12 inhibitor 5–7 days pre-op if bleeding risk high.

— Continue β-blockers perioperatively — never abruptly stop (rebound ischemia, arrhythmia).

Immediate ED transfer (call 911):

Same-day/urgent cardiology referral (not necessarily ED):

Routine cardiology referral:

Pre-op risk in stable angina (RCRI / ACC-AHA 2024):

CCS pearl: In a CCS simulation of stable angina worsening at home, transfer to ED, place on telemetry, IV access, oxygen if SpO₂ <90%, aspirin 325 mg chewed, sublingual nitroglycerin, obtain ECG and troponin, and consult cardiology — treat as ACS rule-out until proven otherwise.

Step 3 management: Patient who completes a stress test in clinic with hypotensive response and 3 mm ST depression → direct admission to telemetry, do not send home pending cardiology follow-up.

Key Differentials — Cardiovascular Same-Category Causes

— Rest pain, prolonged (>20 min), new pattern, troponin positive (NSTEMI/STEMI), dynamic ECG changes.

— Same atherosclerotic substrate — distinguished by symptom pattern and biomarkers.

— Young patients, smokers, often women. Rest pain, especially nocturnal/early morning, cyclic pattern.

— Transient ST elevation during episode; provoked by acetylcholine or ergonovine on cath.

— Treatment: CCBs (diltiazem, amlodipine) + long-acting nitrates; avoid β-blockers (unopposed α → worsens spasm). Smoking cessation critical.

— Exertional angina with normal epicardial coronaries; reduced coronary flow reserve.

— More common in women; managed with β-blocker, ACEi, statin, ranolazine.

— Exertional angina (despite normal coronaries in 50%), syncope, dyspnea triad.

— Late-peaking systolic ejection murmur, diminished/absent S2.

— Echo confirms; severe AS with symptoms → AVR (TAVR or surgical).

— Young patient, exertional chest pain, syncope, family history of sudden death.

— Dynamic LVOT obstruction murmur ↑ with Valsalva/standing.

— Avoid nitrates and DHP CCBs (worsen obstruction).

— Exertional dyspnea may mimic angina; coexists frequently.

— Sharp, pleuritic, positional (worse supine, better leaning forward); friction rub; diffuse ST elevation with PR depression.

— Sudden tearing pain radiating to back, asymmetric pulses/BP, widened mediastinum on CXR. CT angiography is diagnostic.

Acute coronary syndrome (UA / NSTEMI / STEMI):

Vasospastic (Prinzmetal/variant) angina:

Microvascular angina (INOCA/MINOCA spectrum):

Aortic stenosis:

Hypertrophic cardiomyopathy:

Heart failure / ischemic cardiomyopathy:

Pericarditis:

Aortic dissection:

Key distinction: Variant angina = rest pain + transient ST elevation + normal coronaries on cath = CCB-first therapy. Stable angina = exertional + ST depression on stress + fixed stenosis = β-blocker-first therapy.

Board pearl: A patient with exertional chest pain, syncope, and a late-peaking SEM has aortic stenosis until proven otherwise — get an echo before stress testing.

Key Differentials — Non-Cardiovascular Causes

— Pulmonary embolism: acute dyspnea, pleuritic pain, tachycardia, hypoxia; Wells score, D-dimer, CTPA.

— Pneumonia/pleurisy: fever, productive cough, focal exam findings.

— Pneumothorax: sudden unilateral pain, ↓breath sounds, hyper-resonance.

— Pulmonary hypertension: exertional dyspnea, syncope, RV heave, loud P2.

— GERD: burning retrosternal pain, postprandial, supine worse, relieved by PPI trial. Can mimic angina and be relieved by nitroglycerin (smooth muscle relaxation) — a classic Step 3 trap.

— Esophageal spasm: intermittent chest pain, dysphagia; manometry diagnostic.

— Peptic ulcer disease: epigastric, food-related.

— Biliary colic / cholecystitis: RUQ, postprandial fatty meal, Murphy sign.

— Pancreatitis: epigastric radiating to back, ↑lipase.

— Costochondritis (Tietze): reproducible chest wall tenderness on palpation.

— Cervical/thoracic radiculopathy.

— Fibromyalgia, rib fracture.

— Panic disorder: acute episodic chest pain, palpitations, paresthesias, sense of doom; normal workup; diagnosis of exclusion in chest-pain patients.

— Comorbid anxiety/depression worsens angina perception.

— Herpes zoster: dermatomal pain preceding rash by 2–3 days.

— Cocaine, methamphetamine, energy drinks — vasospasm and demand ischemia.

— Carbon monoxide poisoning — headache, chest pain in cluster of household members.

Pulmonary causes:

Gastrointestinal causes:

Musculoskeletal:

Psychiatric:

Dermatologic:

Toxic/metabolic:

Key distinction: Nitroglycerin relief is not specific for cardiac ischemia — it also relieves esophageal spasm and biliary colic. Reproducibility of chest wall pain on palpation does not rule out CAD (15% of MI patients have reproducible tenderness).

Board pearl: Young patient, cocaine use, chest pain, ST changes → benzodiazepines first, then nitrates and CCBs. Avoid β-blockers acutely (unopposed α vasoconstriction).

Secondary Prevention and Long-Term Management Plan

— Aspirin 81 mg daily indefinitely.

— ACEi (or ARB) if HTN, DM, CKD, LVEF <40%, or recent MI.

— β-blocker × ≥3 years post-MI; indefinitely if LVEF <40%.

— Target <130/80 mmHg in established CAD.

— Weight loss: BMI 18.5–24.9, waist circumference <40 in (M) / <35 in (F).

— High-intensity statin; LDL goal <70 mg/dL (consider <55 in very high-risk).

— Ezetimibe → PCSK9i / inclisiran / bempedoic acid as needed.

— Complete smoking cessation — counsel at every visit; offer varenicline, bupropion, NRT.

— Address vaping and secondhand smoke.

— Mediterranean or DASH diet; reduce saturated fats, processed foods, added sugars, sodium <2.3 g/day.

— Diabetes: A1c goal individualized (~7% most adults; 7.5–8% in frail elderly).

— Prefer SGLT2 inhibitors (empagliflozin, dapagliflozin) and GLP-1 RAs (semaglutide, liraglutide) for diabetic CAD — cardiovascular benefit independent of glucose lowering.

— ≥150 min/week moderate-intensity aerobic activity + 2 days resistance training.

— Formal cardiac rehabilitation post-MI, post-PCI, post-CABG, or with chronic stable angina (Class I, underutilized).

— Screen and treat depression (PHQ-9) — increases mortality in CAD.

— Alcohol ≤1 drink/day women, ≤2 drinks/day men.

The "ABCDE" framework for stable CAD secondary prevention:

A — Antiplatelet, ACEi, Anti-anginals:

B — Blood pressure, Body weight:

C — Cholesterol, Cigarettes:

D — Diet, Diabetes:

E — Exercise, Education, Emotional health, Etoh:

Vaccinations: Annual influenza, pneumococcal (PCV20 or PCV15+PPSV23), COVID-19, RSV if eligible.

Step 3 management: At every stable angina follow-up, document: BP, HR, lipid panel, A1c, smoking status, medication adherence, symptom class (CCS), and referral to cardiac rehab if not yet completed.

Board pearl: Cardiac rehab reduces all-cause mortality by ~20% in CAD and is massively underprescribed — order it for every eligible patient.

Follow-Up, Monitoring Parameters, and Counseling

— Newly diagnosed/uptitrating meds: 2–6 weeks for symptom and side effect check.

— Stable on OMT: every 4–6 months initially, then annually if asymptomatic.

— Lipids: 4–12 weeks after statin start/change, then annually.

— A1c: q3 months if uncontrolled, q6 months if at goal.

— BP: every visit; home BP log encouraged.

— Renal function and K within 1–2 weeks of starting or uptitrating ACEi/ARB/MRA, then periodically.

— LFTs at baseline before statin; repeat only if symptoms or other indications.

— CK only with myalgia symptoms — not routine.

— ECG annually or with symptom change.

— Repeat echo if LV function change suspected or after MI (3 months post-MI).

— Not routinely repeated in asymptomatic patients (low yield).

— Repeat for new or worsening symptoms, ≥2 years post-PCI symptomatic, or before high-risk non-cardiac surgery in CCS III–IV.

— Sublingual nitroglycerin: Sit down, take 1 tab/spray, repeat q5 min × 3; call 911 if pain persists after first dose (updated AHA — earlier than the old "after 3 doses" rule).

— Store NTG in dark, original container; replace every 6 months (loses potency).

— Avoid PDE5 inhibitors within 24 h (sildenafil) or 48 h (tadalafil) of nitrate use.

— Sexual activity is generally safe if patient tolerates 3–5 METs (climbing 2 flights without symptoms).

— Air travel safe in stable angina if symptoms controlled; carry NTG.

— Driving: most stable angina patients may drive; restrict if CCS IV or after recent MI/PCI per local regs.

Follow-up cadence (Step 3 longitudinal thinking):

Monitoring labs:

Stress test repeat:

Patient counseling pearls:

Cardiac rehabilitation: 36 sessions over 12 weeks, covered by Medicare for MI, CABG, PCI, stable angina, HF with reduced EF, valve surgery, transplant.

CCS pearl: At every follow-up, explicitly ask about angina frequency, NTG use per week, and exercise tolerance — these guide titration decisions.

Board pearl: Sudden increase in NTG use (e.g., 1/week → 5/week) is functionally unstable angina — escalate workup.

Ethical, Legal, and Patient Safety Considerations

— Document discussion of risks/benefits of OMT vs. revascularization. Post-ISCHEMIA, patients should understand that PCI in stable CAD does not reduce mortality or MI but does improve symptoms — a key shared decision-making point.

— Consent for cardiac catheterization includes contrast nephropathy, bleeding, stroke, dissection, emergent CABG.

— Use validated tools (e.g., Mayo Clinic CHEST PAIN CHOICE decision aid).

— Document patient values about pill burden, procedure risk, and lifestyle change.

— Post-PCI discharge: ensure clear DAPT duration, avoid premature discontinuation (stent thrombosis risk). Document in discharge summary and communicate to PCP and dentists/surgeons.

— Medication reconciliation at every transition — duplicated β-blockers or interacting agents (diltiazem + simvastatin) are common harms.

— Patients on long-acting nitrate must understand the PDE5 inhibitor interaction before any urology/sexual medicine prescription.

— Commercial drivers (CDL) and pilots have stricter return-to-work standards after MI/PCI (typically 3–6 months with negative stress test).

— Document fitness for occupational duties.

— Sudden incapacitation risk in commercial drivers, pilots, train operators may trigger reporting obligations per state/federal law (e.g., FAA Class I medical, FMCSA).

— In refractory angina or end-stage CAD, discuss palliative care, advance directives, code status. Symptom-focused therapy (opioids, ranolazine, EECP) is appropriate.

— Women, Black, and Hispanic patients receive less guideline-directed therapy and revascularization. Audit your own practice patterns.

— Stopping β-blocker abruptly → rebound tachycardia, ischemia.

— Co-prescribing nitrate + PDE5 inhibitor → life-threatening hypotension.

Informed consent — antianginal therapy and procedures:

Shared decision-making (Class I in stable CAD):

Transition-of-care safety risks (high-yield Step 3):

Driving and occupation:

Mandatory disclosure:

End-of-life and goals of care:

Health equity:

Patient safety alert — never events:

Step 3 management: Before discharge after PCI, explicitly counsel and document DAPT duration, NTG use, and PDE5 inhibitor warning. Send structured handoff note to PCP within 48 hours.

High-Yield Associations and Rapid-Fire Clinical Facts

— ISCHEMIA (2020): OMT non-inferior to early invasive in stable CAD with moderate–severe ischemia.

— COURAGE (2007): PCI + OMT not better than OMT alone for death/MI in stable CAD.

— FREEDOM (2012): CABG > PCI in diabetics with multivessel CAD.

— SYNTAX: CABG > PCI for complex 3-vessel/LM disease (high SYNTAX score).

— EXCEL/NOBLE: Mixed signals — CABG and PCI comparable in low–intermediate complexity LM disease.

— HOPE/EUROPA: ACEi (ramipril, perindopril) reduce CV events in stable CAD.

— IMPROVE-IT: Ezetimibe + statin > statin alone post-ACS.

— FOURIER/ODYSSEY: PCSK9 inhibitors reduce events on top of statin.

— Verapamil + simvastatin/lovastatin → ↑statin levels (CYP3A4) → myopathy.

— Grapefruit juice inhibits CYP3A4 → ↑simvastatin, amlodipine levels.

— Amiodarone + simvastatin → cap simvastatin at 20 mg.

— Clopidogrel + omeprazole/esomeprazole → ↓clopidogrel activation (use pantoprazole instead).

— Wellens syndrome (deep symmetric T inversions V2–V3) → critical proximal LAD stenosis.

— De Winter T waves (upsloping ST depression + tall T waves) → proximal LAD occlusion.

— aVR ST elevation > V1 → left main or 3-vessel disease.

— Inferior MI / RCA: bradycardia, AV block, RV infarct (preload-dependent — avoid nitrates).

— Anterior MI / LAD: pump failure, cardiogenic shock, anterior wall MI = worst prognosis.

— Diabetes mellitus, CKD stage ≥3, PAD, abdominal aortic aneurysm, prior ischemic stroke.

— Best mortality benefit in stable CAD: smoking cessation.

— Single most underused therapy: cardiac rehab.

— First-line antianginal: β-blocker.

— Most dangerous combo: nitrate + sildenafil.

— Avoid in Prinzmetal: β-blockers, aspirin (high dose).

Trial-name associations (memorize):

Drug pearls:

ECG associations:

Anatomic associations:

Risk equivalents (treat aggressively):

Rapid-fire:

Board pearl: aVR ST elevation with diffuse ST depression on a stable angina patient's ECG → emergent cath for left main disease.

Board Question Stem Patterns

— 60-year-old man with exertional substernal pressure, HR 82, BP 142/88, on aspirin and atorvastatin. Next best step: start metoprolol succinate (β-blocker first-line, also addresses HTN).

— Patient on metoprolol with persistent angina, HR 58. Add what? Amlodipine (DHP CCB safe with β-blocker). Not verapamil/diltiazem (bradycardia, AV block risk).

— 38-year-old smoker with recurrent nocturnal chest pain, ECG during episode shows transient ST elevation, cath normal. Treatment: diltiazem + smoking cessation; avoid β-blockers.

— Patient with stable angina on β-blocker scheduled for hip replacement. Management: continue β-blocker perioperatively; do not initiate new β-blocker just before surgery (POISE trial harm).

— DES placed 4 months ago, needs elective cholecystectomy. Action: delay surgery to ≥6 months post-DES; continue aspirin perioperatively if proceeding urgently.

— Stable angina on OMT, mild residual symptoms, stress test shows moderate ischemia. Recommend: continue OMT; shared decision-making for PCI for QOL only — no mortality benefit.

— On max β-blocker, amlodipine, nitrate, still angina; HR 55, BP 105/65. Add: ranolazine (no HR/BP effect).

— Patient on isosorbide mononitrate took sildenafil 4 h ago, presents with syncope, BP 70/40. Manage: IV fluids, Trendelenburg, avoid additional nitrates; α-agonists (phenylephrine) if refractory.

— Stable CAD on atorvastatin 80, develops myalgias, CK 4× ULN. Action: hold statin, recheck CK, restart lower dose or switch to rosuvastatin/pravastatin after resolution.

— Diabetic with 3-vessel CAD, LVEF 32%. Best revascularization: CABG > PCI (FREEDOM, STICH).

Stem 1 — Choose first-line antianginal:

Stem 2 — Drug combination trap:

Stem 3 — Variant angina:

Stem 4 — Pre-operative management:

Stem 5 — Post-PCI DAPT and surgery:

Stem 6 — ISCHEMIA application:

Stem 7 — Refractory angina:

Stem 8 — Nitrate–PDE5 interaction:

Stem 9 — Statin myopathy:

Stem 10 — High-risk anatomy:

CCS pearl: When the stem mentions "no relief after 3 sublingual NTG" — escalate to ED/ACS pathway, even if outpatient-seeming.

Board pearl: "Pedal edema on amlodipine" → answer is add ACEi/ARB or switch DHP, never "add furosemide."

One-Line Recap

Stable angina is managed first by aggressive risk-factor optimization and mortality-reducing therapy (aspirin, high-intensity statin, ACEi when indicated), then by symptom-directed antianginals (β-blocker first, then DHP CCB or long-acting nitrate, then ranolazine), reserving revascularization for high-risk anatomy or symptoms refractory to optimal medical therapy — because, per ISCHEMIA, PCI improves quality of life but not mortality in stable CAD.

Mortality-reducing pillars: aspirin 81 mg + high-intensity statin (LDL <70) + ACEi (if HTN/DM/CKD/LVEF<40%/post-MI) + smoking cessation + cardiac rehab + BP <130/80.

Symptom-relief ladder: β-blocker (HR goal 55–60) → add amlodipine or long-acting nitrate (with 10–12 h nitrate-free interval) → add ranolazine → cath/revascularization. Never combine non-DHP CCB with β-blocker.

Revascularization picks (Step 3 favorites): CABG for left main, 3-vessel disease especially with diabetes (FREEDOM) or LVEF <35% (STICH); PCI for refractory single/multi-vessel without these high-risk features.

Highest-yield safety traps: nitrate + PDE5 inhibitor (lethal hypotension), abrupt β-blocker withdrawal (rebound ischemia), β-blocker in Prinzmetal variant (worsens spasm), amlodipine edema treated with diuretic (wrong — add ACEi/ARB or switch agent), DES + premature surgery <6 months post-PCI (stent thrombosis).

CCS pearl: Document at every visit: CCS class, weekly NTG use, BP, HR, LDL, A1c, smoking status, and cardiac rehab referral — this is the longitudinal scaffold Step 3 rewards.

Board pearl: When in doubt, the right answer for stable angina is almost always optimize medical therapy first — not catheterize.